drugset / Trial / NCT00373243
A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will assess the pharmacokinetics and tolerability of a single dose of GW406381 in subjects with moderate hepatic impairment in comparison to matched healthy volunteers. The hepatically impaired and healthy groups will be given a single 20 mg oral dose of GW406381. Blood samples for PK analysis will be collected pre-dose and over the 72 hours post dosing. Subjects will be housed from the evening before dosing until 24 hours after dosing. A follow-up visit will be conducted between 7 to 10 days from the last dose of study drug.
Timeline
- Start
- 2005-10-19
- Primary completion
- 2006-09-26
- Completion
- 2006-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GW406381 | Small molecule | 20 mg | Oral |
Indications
No indication recorded.